SDZ RAD IN STABLE LUNG TRANSPLANT RECIPIENTS WITH CYSTIC FIBROSIS
$0M01FY2000RRNIH
Vanderbilt University, Nashville TN
Investigators
Linked publications & trials
Paper 33558372Paper 32454300Paper 29993499Paper 28369419Paper 28194433Paper 27832858Paper 27718206Paper 27498869Paper 26967998Paper 26908300Paper 26677460Paper 26637290Paper 26411798Paper 26125411Paper 26120597Paper 26055866Paper 26009829Paper 25990642Paper 25936660Paper 25884888Paper 25869442Paper 25820827Paper 25765720Paper 25734077Paper 25660347Paper 25641887Paper 25261246Paper 25232828Paper 25118837Paper 25117929Paper 25026915Paper 24939976Paper 24768120Paper 24752680Paper 24699314Paper 24637543Paper 24384588Paper 24349219Paper 24290979Paper 24284293Paper 24121755Paper 24037626Paper 23972786Paper 23956809Paper 23884469Paper 23863960Paper 23863228Paper 23799953Paper 23786504Paper 23630356Paper 23600543Paper 23592367Paper 23557458Paper 23543059Paper 23523131Paper 23503447Paper 23502781Paper 23385328Paper 23337848Paper 23288871Paper 23279924Paper 23241069Paper 23229731Paper 23204253Paper 23195626Paper 23106931Paper 23106930Paper 23106929Paper 23106928Paper 23106927Paper 23106926Paper 23106925Paper 23106924Paper 23106923Paper 23073617Paper 23040286Paper 22760537Paper 22723323Paper 22721633Paper 22648267Paper 22570963Paper 22552860Paper 22537984Paper 22435735Paper 22360812Paper 22354163Paper 22287587Paper 22198906Paper 22160300Paper 22088886Paper 21964369Paper 21858673Paper 21716327Paper 21633409Paper 21605660Paper 21572029Paper 21533241Paper 21490026Paper 21420789Paper 21420510
Abstract
The pharmacokinetics of SDZ RAD (a deivative of Rapamycin) may be different in lung transplant recipients w/pancreatic insufficient cystic fibrosis. SPECIFIC AIMS: 1) To compare the pharmacokinetics of two different single oral doses of SDZ RAD during steady state administration of Neoral in stable lung transplant receipients w/pancreatic insufficient cystic fibrosis. 2) To assess the effect of two different single oral doses of SDZ RAD on the steady state pharmacokinetics profile of Neoral. 3)To evaluate the safety and tolerability of two different single oral doses of SDZ RAD in stable lung transplant recipients w/pancreatic insufficient cystic fibrosis.
View original record on NIH RePORTER →